InvestSMART

Mesoblast Limited (ASX:MSB)

ALERT: Price-sensitive ASX Announcement for MSB
Current share price for MSB : $1.950 -0.47 (-19.42%)+
Announcement
Release
27 Feb 2026 9:02AM
Price at Release
$2.420
Full Release
download
Summary
Mesoblast Limited, a leader in allogeneic cellular medicines, announced their financial and operational results for the half-year ending December 31, 2025. The successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) has driven substantial revenue growth with gross sales of US$57.0 million. The company reported a net loss of US$40.2 million, an improvement over the previous year. Ryoncil® is now covered by government and commercial payers, reaching 280 million U.S. lives. Mesoblast plans to expand the indications of Ryoncil® for lifecycle extension to treat both adults and children with inflammatory conditions. They also received positive FDA feedback for trials of their second product, rexlemestrocel-L. Financial stability is bolstered by a US$125.0 million non-dilutive credit-line facility.
Key Points
  • Successful U.S. commercial launch of Ryoncil® generated significant revenue growth.
  • Ryoncil® gross sales reached US$57.0 million, with revenue of US$48.7 million after adjustments.
  • Net loss improved to US$40.2 million compared to US$47.9 million in the previous year.
  • Ryoncil® covered by both government and commercial payers, extending to 280 million U.S. lives.
  • Mesoblast aims to expand Ryoncil® indications for lifecycle extension in adults and children.
  • Phase 3 trial for Ryoncil® as second-line treatment for adults with SR-aGvHD is planned.
  • Positive feedback received from FDA for Ryoncil® and rexlemestrocel-L trials.
  • Financial stability supported by US$125.0 million non-dilutive credit-line facility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.